Class: Extraction/Preservation (151)
Patent Number: 6110739
This patent covers generation of cells from embryonic stem cells, and subsequent immortalization of the generated cells. The generated cells may be semidifferentiated stem cells or precursor cells. Immortalization may be accomplished by transfection with the gene HOX 11.
Inventors: Keller, Gordon M. (Denver, CO); Hawley, Robert G. (Toronto, CA); Choi, Kyunghee (Baltimore, MD)
Assignee: National Jewish Medical and Research Center (Denver, CO)
Date of First Priority Issue: Monday November 21st, 1994
Patent Number: 5677136
This patent teaches that the protein CD59 may be used as a marker of hematopoietic stem cells both for identification, and also for purification.
Inventors: Simmons, Paul J. (Adelaide, AU); Hill, Beth L. (Mountain View, CA); Chen, Benjamin P. (Fremont, CA)
Assignee: Systemix, Inc. (Palo Alto, CA)
Date of First Priority Issue: Monday November 14th, 1994
Patent Number: 5665557
This patent covers the use of CDw109 for purification and identification of hematopoietic stem cells.
Inventors: Murray, Lesley (San Jose, CA); Sutherland, D. Robert (Oakville, CA)
Assignee: Systemix, Inc. (Palo Alto, CA) The Toronto Hospital Research Institute (Toronto, CA)
Date of First Priority Issue: Monday November 14th, 1994
Patent Number: 6066451
This patent provides a marker for the identification of specific neural cells. This marker is useful for knowing the quantity and quality of neurons generated from various stem cell populations.
Inventors: Avraham, Shalom (Brookline, MA); Avraham, Hava (Brookline, MA); Groopman, Jerome E. (Brookline, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Date of First Priority Issue: Monday October 3rd, 1994
Patent Number: 5827742
This patent takes advantage of the fact that early hematopoietic stem cells are usually CD34+ and quiescent. By treatment of CD34+ cells with cytotoxic agents that kill proliferating cells, a population of primitive stem cells may be obtained.
Inventor: Scadden, David T. (Weston, MA)
Assignee: Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Date of First Priority Issue: Thursday September 1st, 1994
Patent Number: 6878542
This patent appears to be a really unique way of expanding stem cells. Essentially the patent teaches to connect a growth factor receptor to a promoter that is only expressed on stem cells, such as the promoter for Oct-4. This way stem cells will express the growth factor receptor. This way if you add the ligand for the receptor the stem cells will proliferate...
Inventors: Smith, Austin Gerard (Edinburgh, GB); Mountford, Peter Scott (Elsdenwid, AU)
Assignee: The University of Edinburgh (GB)
Date of First Priority Issue: Thursday April 21st, 1994
Patent Number: 6146888
In this patent an antibiotic resistance gene is placed under the control of a promoter associated with stem cells. This way only the stem cells will live while the other cells will die when exposed to the antibiotic.
Inventors: Smith, Austin Gerard (Edinburgh, GB); Mountford, Peter Scott (Elsfernwid, AU)
Assignee: The University of Edinburgh (GB)
Date of First Priority Issue: Thursday April 21st, 1994
Patent Number: 6399300
This patent teaches ways of purifying out cells expressing myocardial genes from a heterogeneous population of stem cells.
Specifically the patent teaches the use of cardiac specific promoters driving expression of markers that can be used to take the cells desired out of a heterogeneous population of cells.
Inventor: Field, Loren J. (Indianapolis, IN)
Assignee: Indiana University Foundation (Bloomington, IN)
Date of First Priority Issue: Tuesday November 16th, 1993
Patent Number: 5811301
This patent teaches ways of genetically modifying stem cells, and their progeny so as to generate a population of cells that is acceptable by all humanity.
Inventor: Cameron, Robert B. (San Francisco, CA)
Assignee: None Stated
Date of First Priority Issue: Tuesday November 16th, 1993
Patent Number: 6555324
This patent covers methods for identifying hematopoietic stem cells based on expression of markers such as CD34, CD38, and various growth factor receptors.
Inventors: Olweus, Johanna (Fremont, CA); Lund-Johansen, Fridtjof (Fremont, CA); Terstappen, Leon Wmm (Palo Alto, CA)
Assignee: Becton Dickinson & Company (Franklin Lakes, NJ)
Date of First Priority Issue: Thursday November 4th, 1993